ALB and chronic inflammatory demyelinating polyradiculoneuropathy: In the most recent diagnostic guidelines for Guillain-Barré syndrome (GBS, 2023) and CIDP (2021), biomarkers such as CSF albumin are considered only supportive diagnostic tools (27, 28).